Replies to post #251654 on Biotech Values

[Mufaso]

re:PFE- Daniglipron qD data timing

1. Will PFE report Daniglipron qD data in conjunction with 1Q24 financials tomorrow?

Hard to tell if it will be announced with the quarterly results although it would make sense. In the Dec 2023 press release announcing the phase 2B results of twice daily danuglipron they said "results from ongoing and future studies of the once-daily danuglipron modified release formulation will inform a potential path forward with an aim to improve the tolerability profile and optimize both study design and execution...Future development of danuglipron will be focused on a once-daily formulation, with pharmacokinetic data anticipated in the first half of 2024." So the trial was ongoing back in December so it could have concluded and been analyzed by now but PFE has been releasing only limited info on this trial since the discontinuation to the twice daily version.

2. If the answer to 1) is yes, what is the probability that the data are good enough to continue development of the compound?

Danuglipron twice daily had a 50% discontinuation rate (vs. 40% in PBO) and only a PBO adjusted weight loss of 8-13% at 32 weeks. I doubt it can be competitive with LLY's orforglipron which is ahead of danuglipron. Personally, I'm baffled as to why PFE continued development of the extended release version given the tolerability/efficacy profile of the twice daily version and I give it a 10% chance of continuing on whenever results are released.